文献速递MDS 与骨髓增殖性肿瘤白血病

MDS/MPN重叠综合征的稳健患者来源异种移植模型再现CMML和JMML的独特特征

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
PubMed 文献 · Blood · 2017-06-02

研究采用表达人GM-CSF、IL-3和干细胞因子的NSGS小鼠,将CMML或JMML患者CD34+细胞或未分离骨髓/外周血单核细胞移植,获得可连续移植且遗传学准确的CMML模型;JMML样本在所有NSGS受体中均成功植入,模型可用于体内评估JAK2/FLT3抑制剂pacritinib。

要点

  • NSGS小鼠支持CMML和JMML患者细胞稳健植入并再现疾病表型。
  • CMML植入细胞为髓系限制性,免疫表型、形态和基因突变与患者一致。
  • 连续移植验证CD34+细胞含CMML疾病起始细胞,模型可用于药物体内评价。

核心结论

  • NSGS小鼠支持CMML和JMML疾病起始细胞及成熟白血病细胞在体内发育,可创建遗传学准确的临床前模型。

研究设计与样本

  • 使用在NOD/SCID-IL2Rγnull背景中转基表达人GM-CSF、IL-3和干细胞因子的NSGS小鼠进行异种移植。
  • 移植CD34+细胞(n=8例患者)或未分离骨髓或外周血单核细胞(n=10例),共82只受体小鼠。
  • JMML原代样本移植至NSGS受体(n=4例患者,n=12只小鼠)。
  • 对继发性NSGS受体进行人CD34+细胞连续移植(2/5例患者,6/11只小鼠)。

主要发现

  • CMML在受体骨髓、脾、肝和肺中稳健植入(n=82只小鼠)。
  • 植入细胞为髓系限制性,匹配对应患者的免疫表型、形态和基因突变。
  • 连续移植后植入水平相似(2/5例患者,6/11只小鼠),验证CD34+细胞含疾病起始细胞。
  • JMML原代样本在所有NSGS受体中成功植入(n=4例患者,n=12只小鼠)。
  • CMML和JMML植入导致受体明显表型异常和致死,便于体内评估JAK2/FLT3抑制剂pacritinib。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap disorders characterized by monocytosis, myelodysplasia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). Currently, there are no available disease-modifying therapies for CMML, nor are there preclinical models that fully recapitulate the unique features of CMML. Through use of immunocompromised mice with transgenic expression of human GM-CSF, interleukin-3, and stem cell factor in a NOD/SCID-IL2Rγnull background (NSGS mice), we demonstrate remarkable engraftment of CMML and JMML providing the first examples of serially transplantable and genetically accurate models of CMML. Xenotransplantation of CD34+ cells (n = 8 patients) or unfractionated bone marrow (BM) or peripheral blood mononuclear cells (n = 10) resulted in robust engraftment of CMML in BM, spleen, liver, and lung of recipients (n = 82 total mice). Engrafted cells were myeloid-restricted and matched the immunophenotype, morphology, and genetic mutations of the corresponding patient. Similar levels of engraftment were seen upon serial transplantation of human CD34+ cells in secondary NSGS recipients (2/5 patients, 6/11 mice), demonstrating the durability of CMML grafts and functionally validating CD34+ cells as harboring the disease-initiating compartment in vivo. Successful engraftments of JMML primary samples were also achieved in all NSGS recipients (n = 4 patients, n = 12 mice). Engraftment of CMML and JMML resulted in overt phenotypic abnormalities and lethality in recipients, which facilitated evaluation of the JAK2/FLT3 inhibitor pacritinib in vivo. These data reveal that NSGS mice support the development of CMML and JMML disease-initiating and mature leukemic cells in vivo, allowing creation of genetically accurate preclinical models of these disorders.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yoshimi A, Balasis ME, Vedder A, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. 2017. PMID: 28576879. doi:10.1182/blood-2017-01-763219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。